Unia Europejska - maltański - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - aġenti antineoplastiċi - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Unia Europejska - maltański - EMA (European Medicines Agency)

olympus biotech international limited - eptotermin alfa - spondylolisthesis - drogi għat-trattament ta 'mard tal-għadam - opgenra huwa indikat għal fużjoni spinali laterali posterolaterali f'pazjenti adulti bi spondylolistshes fejn l-awtograft naqas jew huwa kontra-indikat.

Unia Europejska - maltański - EMA (European Medicines Agency)

olympus biotech international limited - eptotermin alfa - fratturi tibjali - mediċini għall-kura ta'mard fl-għadam, proteini morfoġenetiċi ta ' għadam - trattament ta 'nonunion ta' tibja ta 'mill-inqas tul ta' 9 xhur, sekondarju għal trawma, f'pazjenti skeletriċi maturi, f'każijiet fejn trattament preċedenti b'autograft ikun falla jew l-użu ta 'autograft ma jkunx fattibbli.

Unia Europejska - maltański - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslicarbazepine acetate - epilessija - anti-epilettiċi, - zebinix huwa indikat bħala terapija adjunctive fl-adulti, adolixxenti u tfal b ' età hawn fuq 6 snin, ma b'sekwestru parzjali-iskoppjar bi jew mingħajr ġeneralizzazzjoni sekondarja.

Unia Europejska - maltański - EMA (European Medicines Agency)

astrazeneca ab - sodium żirkonju cyclosilicate - iperkalemija - il-prodotti terapewtiċi l-oħra kollha - lokelma huwa indikat għall-kura ta ' l-iperkalemija f'pazjenti adulti.

Unia Europejska - maltański - EMA (European Medicines Agency)

lipomed gmbh - thalidomide - majloma multipla - immunosoppressanti - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Unia Europejska - maltański - EMA (European Medicines Agency)

allergan pharmaceuticals international limited - eluxadoline - irritable bowel syndrome; diarrhea - antidiarrheals, intestinali anti-infjammatorji / antiinfective aġenti - truberzi huwa indikat fl-adulti għat-trattament tas-sindromu tal-musrana irritabbli bid-dijarea (ibs d).

Unia Europejska - maltański - EMA (European Medicines Agency)

krka, d.d., novo mesto  - telmisartan - pressjoni għolja - antagonisti ta 'angiotensin ii, sempliċi - hypertensiontreatment ta'l-ipertensjoni essenzjali fl-adulti. kardjovaskulari preventionreduction tal-morbidità kardjovaskulari f'pazjenti bi: - manifest aterotrombotiċi mard kardjovaskulari (passat ta ' mard koronarju tal-qalb jew mard arterjali periferali) jew;dijabete tat-tip 2 mellitus dokumentata ħsara fl-organu milqut.

Unia Europejska - maltański - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacine hydrochloride - tnaqqis tad-defiċit ta 'l-attenzjoni b'hérapectivity - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv għandhom ikunu użati bħala parti minn komprensiva adhd-programm tat-trattament, tipikament inkluż psikoloġiċi, l-edukazzjoni u l-miżuri soċjali.

Unia Europejska - maltański - EMA (European Medicines Agency)

medac gesellschaft fuer klinische spezialpraeparate mbh - asparaginasa - leukimija limfoblastika taċ-Ċelluli prekursuri-linfoma - aġenti antineoplastiċi - spectrila huwa indikat bħala komponent ta 'terapija ta' kombinazzjoni antineoplastika għat-trattament ta 'lewkimja limfoblastika akuta (all) f'pazjenti pedjatriċi minn twelid sa 18-il sena u adulti.